Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory. Only part of the virus's DNA is used in the vaccine and the vaccine itself cannot cause HIV infection or AIDS. In addition to HIV DNA, the vaccine contains interleukin-2 (IL-2) DNA fused to a portion of immunoglobulin (Ig) DNA. IL-2 is a chemical that stimulates the immune system and may improve response to the vaccine.
Study hypothesis: The IL-2/Ig plasmid will be very well tolerated in humans.
Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)|
- Clinical observation and monitoring of hematological, chemical, and immunologic parameters
- local and systemic adverse reactions after each injection and for 12 months after last injection
|Study Start Date:||December 2003|
|Study Completion Date:||December 2006|
Over 90% of the 40 million people infected with HIV live in developing countries and have little or no access to antiretroviral medications. The worldwide HIV/AIDS epidemic will only be controlled through development of a safe and effective vaccine that will prevent HIV infection. DNA vaccines are inexpensive to construct, readily produced in large quantities, and stable for long periods of time. The DNA vaccine in this study, VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env), uses multiple gene products to increase the breadth of the immune response across different HIV subtypes. The DNA plasmids in VRC-HIVDNA009-00-VP code for proteins from HIV subtypes A, B, and C, which together represent 90% of new HIV infections in the world.
The study vaccine is administered with an adjuvant. The adjuvant is a DNA plasmid encoding interleukin 2 (IL-2) fused to the Fc portion of IgG for enhanced stability. This IL-2/Ig adjuvant may augment the immune system's response to the vaccine.
Participants in this study will be randomly assigned to receive either the vaccine and adjuvant, the vaccine and placebo, the adjuvant and placebo, or placebo alone. All injections will be administered by needle-free injection in the upper arm. Participants will receive four does of vaccine: one at their first study visit and then at Months 1, 2, and 6. Participants will have a follow-up visit 2 days after each injection. Some participants may receive another injection at this follow-up visit. All study participants will be followed for 18 months and will have 16 to 20 study visits. Study visits will last 1/2 to 2 hours and will include blood and urine tests and a physical exam. Participants will also have six HIV tests over the course of the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00069030
|United States, Maryland|
|Project Brave HIV Vaccine CRS|
|Baltimore, Maryland, United States, 21201|
|United States, Massachusetts|
|Brigham and Women's Hosp. CRS|
|Boston, Massachusetts, United States, 02115|
|Fenway Community Health Clinical Research Site (FCHCRS)|
|Boston, Massachusetts, United States, 02215|
|United States, New York|
|NY Blood Ctr./Bronx CRS|
|Bronx, New York, United States, 10456|
|HIV Prevention & Treatment CRS|
|New York, New York, United States, 10032|
|NY Blood Ctr./Union Square CRS|
|New York, New York, United States, 10003|
|United States, Rhode Island|
|Miriam Hospital's HVTU|
|Providence, Rhode Island, United States, 02906|
|Study Chair:||Raphael Dolin, MD||Harvard Medical School|